Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging
Rabah Alreshq(Boston University), Frederick L. Ruberg(Boston University), John L. Berk(Boston University), Lisa Mendelson(Boston University), Deepa M. Gopal(Boston University), Tracy Joshi(Boston University), Brian Lilleness(Boston University), Matthew Cozzolino(Boston University), Eric T. Guardino(Boston University), Omar K. Siddiqi(Boston University), Alexandra Pipilas(Boston University), Varsha Muralidhar(Boston University), Vaishali Sanchorawala(Boston Medical Center)
Cited by 8
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
|Science|2017|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k